看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。6 r* y6 c# t1 t, w5 c0 f- k! [( _
) h n; J# W0 @( V
1 ^; L5 T6 M$ T8 X; [! U) t
Currently available feasibility data for possible combination strategies.
& W+ p; ~+ p% ?, s+ W* N8 t( A+ B! n( {————————————————————————————————1 C8 l: k7 d3 C, C
Combination Feasibility according to preliminary data ) `* J$ |# x1 A' d; K/ |1 l# Q
——————————————————————————————————/ S) G8 R3 F$ k( e
Bevacizumab + sorafenib Yes, reduced dose ) z. z1 i* w8 T* o/ ]0 _
Bevacizumab + sunitinib† No / ]5 g6 x8 n( o- ?% w
Bevacizumab + temsirolimus Yes $ d( D( ?) I! H; N9 L. a8 Y
Bevacizumab + everolimus Yes + D$ p3 m/ m+ E) `4 S
Sorafenib + sunitinib ? / M$ s7 }6 A) x0 ]. @ B; R" H: e
Sorafenib + temsirolimus Yes, reduced dose
) y2 Y$ d+ H6 p% WSorafenib + everolimus Yes, reduced dose 2 c% V! J6 Z1 V7 B7 k/ T2 i
Sunitinib + temsirolimus† No 3 ]! P s* M0 A& O5 ?8 I$ z
Sunitinib + everolimus ? % S" _' [& T, j8 V. r5 |; C; e
Temsirolimus + everolimus ? # G/ ^% ?) |1 Z
————————————————————
: J" Q3 `% f9 I: Y7 W/ T†Led to US FDA warning.
& r' l6 h5 C% d& D?: As yet unattempted combination.
A. p6 h# j8 v8 \$ ~4 P) V |
显身卡
& U# b! \: j6 n) U% h+ d
